Nature Communications (Jul 2019)

Molecular retargeting of antibodies converts immune defense against oncolytic viruses into cancer immunotherapy

  • Julia Niemann,
  • Norman Woller,
  • Jennifer Brooks,
  • Bettina Fleischmann-Mundt,
  • Nikolas T. Martin,
  • Arnold Kloos,
  • Sarah Knocke,
  • Amanda M. Ernst,
  • Michael P. Manns,
  • Stefan Kubicka,
  • Thomas C. Wirth,
  • Rita Gerardy-Schahn,
  • Florian Kühnel

DOI
https://doi.org/10.1038/s41467-019-11137-5
Journal volume & issue
Vol. 10, no. 1
pp. 1 – 14

Abstract

Read online

The efficacy of oncolytic adenoviruses is limited by strong immune responses being induced against the oncolytic virus itself. Here, the authors generate a bispecific molecule capable of redirecting the adenovirus-specific antibodies to tumour cells and show this induces immune mediated cancer growth inhibition and enhances the therapeutic efficacy of viral oncolysis.